Rate and Amplification of Drug Resistance among Previously-Treated Patients with Tuberculosis in Kampala, Uganda

Simple item page
dc.contributor.authorTemple, Beth
dc.contributor.authorAyakaka, Irene
dc.contributor.authorOgwang, Sam
dc.contributor.authorNabanjja, Helen
dc.contributor.authorKayes, Susan
dc.contributor.authorNakubulwa, Susan
dc.contributor.authorWorodria, William
dc.contributor.authorLevin, Jonathan
dc.contributor.authorJoloba, Moses
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorEisenach, Kathleen D.
dc.contributor.authorMcNerney, Ruth
dc.contributor.authorElliott, Alison M.
dc.contributor.authorSmith, Peter G.
dc.contributor.authorMugerwa, Roy D.
dc.contributor.authorEllner, Jerrold J.
dc.contributor.authorJones-Lopez, Edward C.
dc.date.accessioned2022-05-17T18:01:34Z
dc.date.available2022-05-17T18:01:34Z
dc.date.issued2008
dc.description.abstractDrug-resistant Mycobacterium tuberculosis has emerged as a global threat. In resource-constrained settings, patients with a history of tuberculosis (TB) treatment may have drug-resistant disease and may experience poor outcomes. There is a need to measure the extent of and risk factors for drug resistance in such patients. Methods. From July 2003 through November 2006, we enrolled 410 previously treated patients with TB in Kampala, Uganda. We measured the prevalence of resistance to first- and second-line drugs and analyzed risk factors associated with baseline and acquired drug resistance. Results. The prevalence of multidrug-resistant TB was 12.7% (95% confidence interval [95% CI], 9.6%–16.3%). Resistance to second-line drugs was low. Factors associated with multidrug-resistant TB at enrollment included a history of treatment failure (odds ratio, 23.6; 95% CI, 7.7–72.4), multiple previous TB episodes (odds ratio, 15.6; 95% CI, 5.0–49.1), and cavities present on chest radiograph (odds ratio, 5.9; 95% CI, 1.2–29.5). Among a cohort of 250 patients, 5.2% (95% CI, 2.8%–8.7%) were infected with M. tuberculosis that developed additional drug resistance. Amplification of drug resistance was associated with existing drug resistance at baseline (P ! .01) and delayed sputum culture conversion (P ! .01). Conclusions. The burden of drug resistance in previously treated patients with TB in Uganda is sizeable, and the risk of generating additional drug resistance is significant. There is an urgent need to improve the treatment for such patients in low-income countries.en_US
dc.identifier.citationTemple, B., Ayakaka, I., Ogwang, S., Nabanjja, H., Kayes, S., Nakubulwa, S., ... & Jones-López, E. C. (2008). Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clinical infectious diseases, 47(9), 1126-1134. DOI: 10.1086/592252en_US
dc.identifier.other10.1086/592252
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3250
dc.language.isoenen_US
dc.publisherClinical infectious diseasesen_US
dc.subjectDrug Resistanceen_US
dc.subjectPatientsen_US
dc.subjectTuberculosisen_US
dc.subjectUgandaen_US
dc.titleRate and Amplification of Drug Resistance among Previously-Treated Patients with Tuberculosis in Kampala, Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Rate and Amplification of Drug Resistance.pdf
Size:
346.55 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences